IN2012MU03359A - - Google Patents

Download PDF

Info

Publication number
IN2012MU03359A
IN2012MU03359A IN3359MU2012A IN2012MU03359A IN 2012MU03359 A IN2012MU03359 A IN 2012MU03359A IN 3359MU2012 A IN3359MU2012 A IN 3359MU2012A IN 2012MU03359 A IN2012MU03359 A IN 2012MU03359A
Authority
IN
India
Prior art keywords
oxo
carboxamide
prodrug
thiophene
chloro
Prior art date
Application number
Other languages
English (en)
Inventor
Sharadchandra Pradhan Dr Nitin
Sudhir Patil Dr Nilesh
Ramchandra Walavalkar Dr Rajesh
Nilesh Subhash Kulkarni Mr
Sandip Babanrao Pawar Mr
Tarak Sambhaji Pawar Mr
Original Assignee
Wanbury Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to PCT/IN2013/000801 priority Critical patent/WO2014102822A2/en
Priority to KR1020157015903A priority patent/KR20150100661A/ko
Priority to CN201380068642.9A priority patent/CN105431429A/zh
Priority to IN3359MU2012 priority patent/IN2012MU03359A/en
Priority to US14/436,018 priority patent/US9359341B2/en
Priority to EP13869179.5A priority patent/EP2897619A4/en
Priority to JP2015550211A priority patent/JP2016504348A/ja
Priority to BR112015011033A priority patent/BR112015011033A2/pt
Application filed by Wanbury Ltd filed Critical Wanbury Ltd
Priority to AU2013368847A priority patent/AU2013368847B2/en
Priority to RU2015112195A priority patent/RU2015112195A/ru
Priority to CA2883323A priority patent/CA2883323A1/en
Priority to MX2015003319A priority patent/MX2015003319A/es
Priority to ZA2015/03700A priority patent/ZA201503700B/en
Publication of IN2012MU03359A publication Critical patent/IN2012MU03359A/en
Priority to PH12015501625A priority patent/PH12015501625A1/en
Priority to HK16105076.8A priority patent/HK1217101A1/zh
Priority to US15/149,998 priority patent/US20160251342A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
IN3359MU2012 2012-12-26 2013-12-24 IN2012MU03359A (da)

Priority Applications (16)

Application Number Priority Date Filing Date Title
AU2013368847A AU2013368847B2 (en) 2012-12-26 2013-12-24 Aldehyde derivative of substitute oxazolidinones
KR1020157015903A KR20150100661A (ko) 2012-12-26 2013-12-24 치환된 옥사졸리디논의 알데히드 유도체
RU2015112195A RU2015112195A (ru) 2012-12-26 2013-12-24 Альдегидное производное замещенных оксазолидинонов
US14/436,018 US9359341B2 (en) 2012-12-26 2013-12-24 Aldehyde derivative of substitute oxazolidinones
EP13869179.5A EP2897619A4 (en) 2012-12-26 2013-12-24 ALDEHYDE DERIVATIVE FROM SUBSTITUTED OXAZOLIDINONES
JP2015550211A JP2016504348A (ja) 2012-12-26 2013-12-24 置換オキサゾリジノンのアルデヒド誘導体
BR112015011033A BR112015011033A2 (pt) 2012-12-26 2013-12-24 derivado aldeído de oxazolidinonas substituídas
PCT/IN2013/000801 WO2014102822A2 (en) 2012-12-26 2013-12-24 Aldehyde derivative of substitute oxazolidinones
CN201380068642.9A CN105431429A (zh) 2012-12-26 2013-12-24 取代的噁唑烷酮类的醛衍生物
IN3359MU2012 IN2012MU03359A (da) 2012-12-26 2013-12-24
CA2883323A CA2883323A1 (en) 2012-12-26 2013-12-24 Aldehyde derivative of substituted oxazolidinones
MX2015003319A MX2015003319A (es) 2012-12-26 2013-12-24 Derivado de aldehido de oxazolidinonas sustituidas.
ZA2015/03700A ZA201503700B (en) 2012-12-26 2015-05-25 Aldehyde derivative of substitute oxazolidinones
PH12015501625A PH12015501625A1 (en) 2012-12-26 2015-07-22 Aldehyde derivative of substitute oxazolidinones
HK16105076.8A HK1217101A1 (zh) 2012-12-26 2016-05-04 取代的噁唑烷酮類的醛衍生物
US15/149,998 US20160251342A1 (en) 2012-12-26 2016-05-09 Aldehyde derivative of substituted oxazolidinones

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN3359MU2012 IN2012MU03359A (da) 2012-12-26 2013-12-24

Publications (1)

Publication Number Publication Date
IN2012MU03359A true IN2012MU03359A (da) 2015-06-26

Family

ID=54242230

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3359MU2012 IN2012MU03359A (da) 2012-12-26 2013-12-24

Country Status (15)

Country Link
US (1) US9359341B2 (da)
EP (1) EP2897619A4 (da)
JP (1) JP2016504348A (da)
KR (1) KR20150100661A (da)
CN (1) CN105431429A (da)
AU (1) AU2013368847B2 (da)
BR (1) BR112015011033A2 (da)
CA (1) CA2883323A1 (da)
HK (1) HK1217101A1 (da)
IN (1) IN2012MU03359A (da)
MX (1) MX2015003319A (da)
PH (1) PH12015501625A1 (da)
RU (1) RU2015112195A (da)
WO (1) WO2014102822A2 (da)
ZA (1) ZA201503700B (da)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160251342A1 (en) * 2012-12-26 2016-09-01 Wanbury Ltd. Aldehyde derivative of substituted oxazolidinones
US9394292B2 (en) 2012-12-26 2016-07-19 Wanbury Ltd. Rivaroxaban intermediate and preparation thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19962924A1 (de) 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
DE10129725A1 (de) * 2001-06-20 2003-01-02 Bayer Ag Kombinationstherapie substituierter Oxazolidinone
DE10300111A1 (de) 2003-01-07 2004-07-15 Bayer Healthcare Ag Verfahren zur Herstellung von 5-Chlor-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid
DE102004002044A1 (de) 2004-01-15 2005-08-04 Bayer Healthcare Ag Herstellverfahren
GT200600196A (es) * 2005-05-23 2007-01-15 Compuestos n-formil de hidroxilamina
DE102005045518A1 (de) 2005-09-23 2007-03-29 Bayer Healthcare Ag 2-Aminoethoxyessigsäure-Derivate und ihre Verwendung
US8188270B2 (en) 2005-10-04 2012-05-29 Bayer Schering Pharma Aktiengesellschaft Polymorphous form of 5-chloro-N-({(5S)-2-oxo-3[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidine-5-yl}-methyl)-2-thiophene carboxamide
DE102006007146A1 (de) 2006-02-16 2007-08-23 Bayer Healthcare Ag Aminoacyl-Prodrugs
DE102006039589A1 (de) * 2006-08-24 2008-03-06 Bayer Healthcare Ag Aminoacyl-Prodrugs II
EP2190841B1 (en) 2007-08-14 2013-05-15 Concert Pharmaceuticals Inc. Substituted oxazolidinone derivatives
US7816355B1 (en) 2009-04-28 2010-10-19 Apotex Pharmachem Inc Processes for the preparation of rivaroxaban and intermediates thereof
ES2905760T3 (es) 2009-07-31 2022-04-12 Krka D D Novo Mesto Procedimientos para la cristalización del rivaroxabán
CN102822167A (zh) 2010-01-04 2012-12-12 埃南蒂亚有限公司 用于制备利伐沙班的方法及其中间体
EP2354128A1 (en) 2010-02-10 2011-08-10 Sandoz Ag Method for the preparation of rivaroxaban
AU2011327903A1 (en) * 2010-11-11 2013-05-02 Redx Pharma Plc Drug derivatives
US9221771B2 (en) 2011-04-11 2015-12-29 Sandoz Ag Method for the preparation of substituted oxazolidinones
GEP20156397B (en) 2011-05-06 2015-11-10 Egis Gyógyszergyár Nyilvánosan Működő Részvénytársaság Process for the preparation of a rivaroxaban and intermediates formed in said process
ES2395304B1 (es) 2011-05-20 2014-01-16 Interquim, S.A. Procedimiento de obtención de una tiofen-2-carboxamida.
US9394292B2 (en) 2012-12-26 2016-07-19 Wanbury Ltd. Rivaroxaban intermediate and preparation thereof

Also Published As

Publication number Publication date
CA2883323A1 (en) 2014-07-03
HK1217101A1 (zh) 2016-12-23
AU2013368847B2 (en) 2017-03-16
US9359341B2 (en) 2016-06-07
BR112015011033A2 (pt) 2017-07-11
WO2014102822A3 (en) 2015-10-29
MX2015003319A (es) 2015-08-14
EP2897619A2 (en) 2015-07-29
AU2013368847A1 (en) 2015-05-28
KR20150100661A (ko) 2015-09-02
CN105431429A (zh) 2016-03-23
PH12015501625A1 (en) 2015-09-28
ZA201503700B (en) 2016-10-26
JP2016504348A (ja) 2016-02-12
WO2014102822A2 (en) 2014-07-03
EP2897619A4 (en) 2016-08-17
US20150259333A1 (en) 2015-09-17
RU2015112195A (ru) 2017-01-31

Similar Documents

Publication Publication Date Title
HK1157759A1 (en) New co-crystal compound of rivaroxaban and malonic acid
HK1130252A1 (en) Aminoacyl prodrug derivatives and medicaments for the treatment of thromboembolitic disorders
DK1934208T3 (da) Ny polymorf form af 5-chlor-N-({(5S)-2-0x0-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid
EA201391647A1 (ru) Способ получения ривароксабана и промежуточные соединения, получаемые в указанном способе
CR20150001A (es) Formas de administración farmacéuticas que comprenden 5-cloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morfolinil) fenil]-1,3-oxazolidin-5-il}metil)-2-tiofencarboxamida
MX2009001977A (es) Derivados profarmacologicos de aminoacilo y medicamentos para el tratamiento de enfermedades tromboembolicas.
PH12015501625A1 (en) Aldehyde derivative of substitute oxazolidinones
WO2012080184A3 (de) Flüssige, oral applizierbare pharmazeutische zusammensetzungen enthaltend 5-chlor-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid
IL250168A0 (en) Crystalline form of 5 – chloro –n ( { (5s) – 2 – oxo – 3 – [ 4 – ( 5,6 – dihydro – 4h – [ 1,2,4 ] triazin-1-yl) phenyl] – 1, 3-oxazolidine-5-yl}methyl)thiophene-2-an innovative carboxamide and pharmaceutical preparations containing it
BR112016024825A2 (pt) composição contendo rivaroxaban e processo para fabricação de uma composição compreendendo rivaroxaban
CU23445A3 (es) Procedimiento de preparación